ribaxamase

Ribaxamase is a recombinant, orally administered β-lactamase enzyme developed to be co-administered with intravenous (IV) β-lactam antibiotics, such as penicillins and cephalosporins. Its primary mechanism of action is the enzymatic degradation of excess IV β-lactam antibiotics that are excreted into the gastrointestinal (GI) tract via bile. By inactivating these antibiotics in the upper GI tract, ribaxamase aims to protect the gut microbiome from antibiotic-induced dysbiosis, thereby reducing the risk of secondary infections like *Clostridium difficile* infection (CDI), antibiotic-associated diarrhea (AAD), and limiting the emergence of antimicrobial resistance. Ribaxamase has been evaluated in Phase II clinical trials for prevention of CDI in patients receiving IV ceftriaxone for lower respiratory tract infections and has shown significant reduction in CDI rates compared to placebo. The drug was originally developed by Ipsat Therapies and further advanced by Theriva Biologics (formerly Synthetic Biologics)[2][3][4][5][6].

Other names

KymeraseBacillus licheniformis isoenzyme